Ads
related to: treatment protocol for multiple myeloma- Primary and Subgroup Data
Primary- and Subgroup-
Specific Data
- Contact a Representative
For Questions and Information
About This Treatment
- Patient Profile
Potential Treatment Candidates
HCPs, See Who May Be Appropriate
- Phase 3 Trial
Explore the Phase 3 Trial Design,
Results, and Patient Population
- Primary and Subgroup Data
Search results
Results from the WOW.Com Content Network
Multiple national cancer treatment guidelines recommend early palliative care for people with advanced multiple myeloma at the time of diagnosis and for anyone who has significant symptoms. [142] [143] Palliative care is appropriate at any stage of multiple myeloma and can be provided alongside curative treatment.
multiple myeloma, AL amyloidosis DA or DAC: daunorubicin x 3 days plus ara-C x 7 days, a variant of 7+3 regimen Acute myeloid leukemia, excluding acute promyelocytic leukemia: DAT: daunorubicin, cytarabine (ara-C), tioguanine: Acute myeloid leukemia: DCEP dexamethasone, cyclophosphamide, etoposide, platinum agent
Pages in category "Chemotherapy regimens used in multiple myeloma" The following 2 pages are in this category, out of 2 total.
Members of the IMWG conduct research to prevent onset of myeloma, improve treatment and find a cure. [8] The working group publishes statements and treatment guidelines in its own name [9] as well as sponsoring publications by its members. The IMF also has the Black Swan Research Initiative (BSRI) in order to work towards finding a cure for ...
Treatment for multiple myeloma is focused on therapies that decrease the clonal plasma cell population and consequently decrease the signs and symptoms of disease. If the disease is completely asymptomatic (i.e. there is a paraprotein and an abnormal bone marrow population but no end-organ damage), as in smouldering myeloma, treatment is ...
FLAG is a chemotherapy regimen used for relapsed and refractory acute myeloid leukemia (AML). [1] The acronym incorporates the three primary ingredients of the regimen: . Fludarabine: an antimetabolite that, while not active toward AML, increases formation of an active cytarabine metabolite, ara-CTP, in AML cells;
The fusion of the B cells with myeloma cells can be done using electrofusion. Electrofusion causes the B cells and myeloma cells to align and fuse with the application of an electric field. Alternatively, the B-cells and myelomas can be made to fuse by chemical protocols, most often using polyethylene glycol.
Multiple myeloma is a hematologic cancer, originating in the bone marrow, which also frequently presents as one or more bone lesions. [10] Germ cell tumors, including teratoma, often present and originate in the midline of the sacrum, coccyx, or both. These sacrococcygeal teratomas are often relatively amenable to treatment. [11]
Ads
related to: treatment protocol for multiple myeloma